Genmab — Marts 2015
-
Det må være det vi kalder en fejl40 i Nordjylland Repsac

-
tror ikke vi har diskuteret det
-
Ja de var nogle svin der... Irriterer mig stadig lidt at Roche lukkede hele Cardio området ned inklusiv Inclaclumab sidste år. Var ellers et stof der var langt fremme
-
Der er nogen som vil ud inden regnskab i dag

-
Revenue increased by DKK 186 million, 28%, from DKK 664 million in 2013 to DKK 850 million in 2014, mainly driven by higher revenue related to our daratumumab and DuoBody collaborations with Janssen, partially offset by lower Arzerra royalties.
•Operating expenses were reduced from DKK 594 million in 2013 to DKK 585 million in 2014.
•Operating income improved by DKK 196 million, from DKK 69 million in 2013 to DKK 265 million in 2014
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind